Table 4.

Changes in heart rate variability and laboratory measurements under metreleptin substitution

Patients	Heart rate variability									Laboratory measurements
	SDNN			HFn(Welch)			LFn(Welch)			metanephrines, pmol/L			normetanephrines, pmol/L			aldosterone, nmol/L
	0	1st	7–14	0	1st	7–14	0	1st	7–14	0	1st	7–14	0	1st	7–14	0	1st	7–14
	weeks	weeks	months	weeks	weeks	months	weeks	week	months	weeks	week	months	weeks	weeks	months	weeks	week	months
Patient 1
Patient 2	29.1	25.6	46.2	0.83	0.77	0.23	0.17	0.23	0.77	154.6	152.1		622.4	436.8		0.5	0.1
Patient 3	38.4	29.6	50.7	0.47	0.34	0.58	0.53	0.66	0.42	261.1	228.2		360.4	600.6		0.2	0.3
Patient 4	42.3	42.3	53.8	0.54	0.44	0.74	0.46	0.56	0.26	273.8	192.7		475.0	376.7		0.0	0.1
Patient 5	27.9	21.0	52.5	0.18	0.18	0.66	0.82	0.82	0.34	364.5		267.2	819.0		501.8	0.1	0.2	0.0
Patient 6	22.8	57.1	46.0	0.32	0.52	0.49	0.68	0.48	0.51	223.1		162.2	862.7		267.5	0.4	0.3	0.6
Mean ± SD	32.1±	35.1±	49.8±	0.47±	0.45±	0.54±	0.53±	0.55±	0.46±	255.4±	191.0±	214.7±	627.9±	471.4±	384.7±	0.3±	0.2±	0.3±
	7.2	13.1	3.2	0.22	0.20	0.17	0.22	0.20	0.17	68.5	31.1	52.5	193.2	94.6	117.1	0.2	0.1	0.3

HFn, normalized high-frequency component; LFn, normalized low-frequency component; SD, standard deviation; SDNN, standard deviation of the normal-to-normal interval.